Reference entry · PTHrP(1-34) analog
Abaloparatide
Also known as: BA058 · Tymlos · PTHrP(1-34) analog
- Class
- PTHrP(1-34) analog
- Size
- 34 amino acids
- Primary targets (literature)
- PTH1 receptor (biased agonism literature)
- Regulatory context
- FDA-approved as Tymlos for high-risk postmenopausal osteoporosis. RUO catalog material is not approved drug without verified sourcing.
Overview
Abaloparatide is an FDA-approved PTHrP analog studied in the ACTIVE phase 3 trial for postmenopausal osteoporosis. Sequence and signaling profile differ from teriparatide despite shared peptide length.
Mechanism in research literature
Selective PTH1 receptor activation with biased signaling literature describing transient cAMP and reduced hypercalcemia vs. teriparatide in ACTIVE comparisons.
Common research focus areas
- ACTIVE trial vertebral and nonvertebral fracture endpoints
- BMD and histomorphometry vs. teriparatide
- Hypercalcemia and cardiovascular safety follow-up
- MS discrimination from teriparatide (same length, different sequence)
Full literature roundup
Read the cited research summary
A PTHrP(1-34) analog with ACTIVE trial fracture data and biased PTH1 receptor signaling. How it differs from teriparatide and what catalog identity requires.
Abaloparatide research roundup · 4 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.